secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atrium Therapeutics, Inc. (RNA)
CIK:        0002093101
Form:       8-K
Filed at:   2026-08-13T20:50:28+00:00
Accession:  0001193125-26-349482
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atrium Therapeutics Q2 2026: IND cleared for ATR 1072, BMS milestone $15M, cash $263.9M
--------------------------------------------------------------------------------

- FDA cleared IND for ATR 1072; Corventis Phase 1/2 trial in PRKAG2 syndrome launched, ~37 participants planned.
- Earned second BMS milestone payment of $15M in August, to be recognized in Q3 2026.
- Q2 2026 collaboration revenue $3.0M; R&D expenses $15.3M; G&A $10.3M.
- Cash, equivalents and short-term investments $263.9M as of June 30, 2026; runway through mid-2028.
- Expect first Corventis participant enrollment by end of 2026; initial data 2H 2027; IND for ATR 1086 in 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2093101/000119312526349482/0001193125-26-349482-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2093101/000119312526349482/d149126d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-349482

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer